Low CSF somatostatin associated with response to nimodipine in patents with affective illness

Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response...

Full description

Saved in:
Bibliographic Details
Published in:Biological psychiatry (1969) 2003-01, Vol.53 (2), p.180-183
Main Authors: Frye, Mark A, Pazzaglia, Peggy J, George, Mark S, Luckenbaugh, David A, Vanderham, Elizabeth, Davis, Candace L, Rubinow, David R, Post, Robert M
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
affective illness
Biological and medical sciences
Calcium Channel Blockers - therapeutic use
cerebrospinal fluid
Cerebrospinal fluid (biochemistry, cytology, circulation, manometry). Intracranial pressure determination
Depression
Double-Blind Method
Female
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Mood disorders
Mood Disorders - cerebrospinal fluid
Mood Disorders - drug therapy
Nimodipine
Nimodipine - therapeutic use
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
somatostatin
Somatostatin - cerebrospinal fluid
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: In patients with depression, treatment with nimodipine has been shown to increase cerebrospinal fluid (CSF) somatostatin (SRIF) and ameliorate baseline global cerebral hypometabolism. This study was conducted to assess whether a low baseline level of CSF SRIF was associated with response to nimodipine treatment. Methods: Twenty-one depressed patients underwent lumbar puncture for analysis of CSF somatostatin-like immunoreactivity (SRIF-LI) during a medication-free period and after at least 6 weeks of nimodipine monotherapy. Twenty-five healthy control subjects were utilized as a comparison group. Clinical improvement was assessed using the Clinical Global Impression Scale for Bipolar Illness. Results: As predicted, baseline CSF SRIF-LI was significantly lower in eventual nimodipine responders (33.1 ± 2.8 pg/mol) compared to eventual nonresponders [41.9 ± 2.6 pg/mL; t(19) = 1.98, p = .03, one-tailed]. Conclusions: Low baseline CSF somatostatin in depression may be associated with response to nimodipine, which in turn may be related to the ability of nimodipine to increase CSF somatostatin.
ISSN:0006-3223
1873-2402
DOI:10.1016/S0006-3223(02)01343-4